La. Jury Hits J&J With $258M Verdict In Risperdal Suit

Law360 (October 15, 2010, 2:58 PM EDT) -- A Louisiana jury has smacked a Johnson & Johnson unit with a $257.7 million verdict in the state's suit against the company for downplaying the link between its antipsychotic drug Risperdal and diabetes.

The jury reached a verdict late Thursday in the 27th Judicial Court, St. Landry Parish, finding that J&J and its unit Janssen Pharmaceutica Inc. made misrepresentations in 2003 and 2004 about the drug's link to diabetes, according to Louisiana Attorney General James D. “Buddy” Caldwell.

“This verdict sends a loud message to those who knowingly try to defraud the system,” Caldwell said. “Those who deceive the state must...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS